How can the EU SoHO Regulation become a framework that would encourage Member States to collect more plasma, with the aim of achieving strategic autonomy, benefitting donors, and improving access to life-saving plasma-derived therapies for rare disease patients?
Based on evidence from a wide range of scientific studies, how to address the misperception that plasma donation implies a significant risk for donors?
How to improve awareness that compensating plasma donors, using a fixed-rate allowance making good for expenses and inconvenience, goes hand-in-hand with the principle of voluntary unpaid donation?
Tune in to the livestream this Monday at 4pm to find out the answers to these important questions and many more, when key industry experts and decision-makers will be sharing their insights during a live-streamed debate from the European Parliament in Brussels.
The "Substances of Human Origin Regulation: a step forward or backwards for patient access to plasma-derived medicines?" event will be moderated by Dave Keating.
The event will be divided into three main key themes: patient access to plasma-derived medicines (PDMPs), the safety of plasma donation and the ethical principles of compensating donors in the context of the SoHO Regulation.
Expert speakers and agenda
16:00 – 16:25
Giles Platford, Chair of the PPTA Global Executive Board
Martine Pergent, President at the International Patient Organisation for Primary Immunodeficiencies
16:28 – 16:52
Svenja Tatjana Barckhausen, Executive Board Member at Haema AG
Dr. Behrouz Mansouri, Medical Director at PlasmaVita Magdeburg
16.55 – 17.30
Begoña Roman Maestre, Professor of Ethics and Bioethics at the University of Barcelona
Stelios Kympouropoulos, Member of the European Parliament, EPP
Live event from the European Parliament with the kind support of Plasma Protein Therapeutics Association (PPTA)
About PPTA
The Plasma Protein Therapeutics Association is the trade association representing the manufacturers of plasma-derived medicinal products (PDMPs) and the private sector plasma collectors, which includes more than 160 centres in Europe.
As a trusted partner to health systems, PPTA drives broad and reliable access to high-quality plasma protein therapies, with a focus on the well-being of patients and plasma donors.
